Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,347.51 +940.19 (+1.48%) CMC Crypto 200
1,379.92 +67.30 (+5.12%)
Acarix AB (publ) (ACARIX.ST)
| Previous close | 0.2440 |
| Open | 0.2445 |
| Bid | 0.2440 x 0 |
| Ask | 0.2450 x 0 |
| Day's range | 0.2365 - 0.2450 |
| 52-week range | 0.1750 - 0.5805 |
| Volume | |
| Avg. volume | 4,293,652 |
| Market cap | 194.08M |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Acarix announces the initiation of the first US-based clinical workflow evaluation study
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stress tests and the CADScor System. The focus is on identifying non-obstructive Coronary Artery Disease (CAD) in chest pain patients, with the ultimate goal of improving discharge from Emergency Departments and Clinics in the United States.
- PR Newswire
New Health Economic Analysis Presented at ACC Highlights the Acarix CADScor System's Cost-Effectiveness
Acarix, a leader in acoustic-based Cardiac Diagnostics, is pleased to announce the results from a 2024 American College of Cardiology (ACC) poster presentation by Suzanne Baron, MD, MSc, Director of Interventional Cardiology Research, Massachusetts General Hospital and Faculty at The Baim Institute for Clinical Research, to assess the cost-utility of the CADScor System for the evaluation of coronary artery disease (CAD) in a low-risk patient population presenting to the Emergency Department (ED)
- PR Newswire
Acarix Strengthens U.S. Team with Three Key Advisors
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors to its team. Joining the advisory board are Ken Nelson, known for his leadership in the MedTech space; Dr. Saumil R. Oza, MD, an experienced electrophysiologist from Ascension Medical Group; and Dave Braun, a strategic and customer-driven executive with over 40 years of experience working in startup and large company environments.
